Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan You

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkASoong-Hoon Kim, John S Tokarski, Kenneth J Leavitt, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitorsKurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Plos One|March 27, 2019
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillanceJinqi Liu, Joshua Curtin, Dan You, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Nature Communications|January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12CMatthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Bioorganic & Medicinal Chemistry Letters|December 7, 2007
Identification of 2-amino-5-(thioaryl)thiazoles as inhibitors of nerve growth factor receptor TrkASoong-Hoon Kim, John S Tokarski, Kenneth J Leavitt, et al.
Bioorganic & Medicinal Chemistry Letters|May 20, 2015
9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitorsKurt Zimmermann, Xiaopeng Sang, Harold A Mastalerz, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine InhibitorsAmy C Hart, Gretchen M Schroeder, Honghe Wan, et al.
Plos One|March 27, 2019
Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillanceJinqi Liu, Joshua Curtin, Dan You, et al.
ACS Medicinal Chemistry Letters|March 18, 2021
Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1Andrew P Degnan, Godwin K Kumi, Christopher W Allard, et al.
Bioorganic & Medicinal Chemistry Letters|February 2, 2011
Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3Lalgudi S Harikrishnan, Muthoni G Kamau, Honghe Wan, et al.
Journal for Immunotherapy of Cancer|January 7, 2021
Enhanced antitumor immunity by a novel small molecule HPK1 inhibitorDan You, Stephen Hillerman, Gregory Locke, et al.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Nature Communications|January 31, 2026
Covalent inhibitor design confers activity against both GDP- and GTP-bound forms of KRAS G12CMatthew L Condakes, Zhuo Zhang, Derek B Danahy, et al.
Pageof 6